Tofacitinib oral sustained release dosage forms
US11253523B2 · kind B2 · utility
0Cited by
13References
98Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2020 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | Mar 13, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.